Suo Y, G Fedor J, Zhang H, Tsolova K, Shi X, Sharma K
bioRxiv. 2024; .
PMID: 39314352
PMC: 11419087.
DOI: 10.1101/2024.09.11.612563.
Kastrinou-Lampou V, Rodriguez-Perez R, Poller B, Huth F, Gaborik Z, Martonne-Toth B
Arch Toxicol. 2024; 98(10):3409-3424.
PMID: 39023798
DOI: 10.1007/s00204-024-03794-3.
Hughes C, Alderman C, Wolin A, Fields K, Zhao R, Ford H
Biochim Biophys Acta Rev Cancer. 2024; 1879(3):189098.
PMID: 38555001
PMC: 11111358.
DOI: 10.1016/j.bbcan.2024.189098.
Lang J, Li L, Quan Y, Tan R, Zhao J, Li M
Front Pharmacol. 2023; 14:1213602.
PMID: 37637422
PMC: 10450745.
DOI: 10.3389/fphar.2023.1213602.
Ueda M, Fukui K, Kamatani N, Kamitsuji S, Matsuo A, Sasase T
J Hum Genet. 2023; 68(10):699-704.
PMID: 37308567
DOI: 10.1038/s10038-023-01168-8.
New insight into the management of renal excretion and hyperuricemia: Potential therapeutic strategies with natural bioactive compounds.
Yang B, Xin M, Liang S, Xu X, Cai T, Dong L
Front Pharmacol. 2022; 13:1026246.
PMID: 36483739
PMC: 9723165.
DOI: 10.3389/fphar.2022.1026246.
A Head-To-Head Comparison of Benzbromarone and Allopurinol on the Risk of Type 2 Diabetes Mellitus in People With Asymptomatic Hyperuricemia.
Lai S, Liao K, Kuo Y, Lin C, Liu C, Hwang B
Front Pharmacol. 2021; 12:731370.
PMID: 34658871
PMC: 8514696.
DOI: 10.3389/fphar.2021.731370.
A historical journey of searching for uricosuric drugs.
Jansen T, Tanja G, Matthijs J
Clin Rheumatol. 2021; 41(1):297-305.
PMID: 34581891
DOI: 10.1007/s10067-021-05930-1.
Antihyperuricemic Effect of Leaf Extract in Rodent Models.
Lee D, Kim J, Han Y, Park K
Evid Based Complement Alternat Med. 2021; 2021:3732317.
PMID: 34335806
PMC: 8324340.
DOI: 10.1155/2021/3732317.
Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases.
Chin Med J (Engl). 2017; 130(20):2473-2488.
PMID: 29052570
PMC: 5684625.
DOI: 10.4103/0366-6999.216416.
Lesinurad: what the nephrologist should know.
Sanchez-Nino M, Zheng-Lin B, Valino-Rivas L, Sanz A, Ramos A, Luno J
Clin Kidney J. 2017; 10(5):679-687.
PMID: 28979780
PMC: 5622894.
DOI: 10.1093/ckj/sfx036.
Critical appraisal of the role of pegloticase in the management of gout.
Ea H, Richette P
Open Access Rheumatol. 2012; 4:63-70.
PMID: 27790013
PMC: 5045100.
DOI: 10.2147/OARRR.S17431.
Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis.
Li S, Yang H, Guo Y, Wei F, Yang X, Li D
Sci Rep. 2016; 6:33082.
PMID: 27605442
PMC: 5015109.
DOI: 10.1038/srep33082.
Gout: optimizing treatment to achieve a disease cure.
Bernal J, Quilis N, Andres M, Sivera F, Pascual E
Ther Adv Chronic Dis. 2016; 7(2):135-44.
PMID: 26977282
PMC: 4772341.
DOI: 10.1177/2040622315618393.
Uricosuric medications for chronic gout.
Kydd A, Seth R, Buchbinder R, Edwards C, Bombardier C
Cochrane Database Syst Rev. 2014; (11):CD010457.
PMID: 25392987
PMC: 11262558.
DOI: 10.1002/14651858.CD010457.pub2.
Structure-activity relationships of benzbromarone metabolites and derivatives as EYA inhibitory anti-angiogenic agents.
Pandey R, Wang T, Tadjuidje E, McDonald M, Rettie A, Hegde R
PLoS One. 2013; 8(12):e84582.
PMID: 24367676
PMC: 3867503.
DOI: 10.1371/journal.pone.0084582.
New advances in the treatment of gout: review of pegloticase.
Reinders M, Jansen T
Ther Clin Risk Manag. 2010; 6:543-50.
PMID: 21127695
PMC: 2988614.
DOI: 10.2147/TCRM.S6043.
Management of hyperuricemia in gout: focus on febuxostat.
Reinders M, Jansen T
Clin Interv Aging. 2010; 5:7-18.
PMID: 20169038
PMC: 2817937.
DOI: 10.2147/cia.s5476.
A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?.
Lee M, Graham G, Williams K, Day R
Drug Saf. 2008; 31(8):643-65.
PMID: 18636784
DOI: 10.2165/00002018-200831080-00002.
Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.
Stocker S, Williams K, McLachlan A, Graham G, Day R
Clin Pharmacokinet. 2008; 47(2):111-8.
PMID: 18193917
DOI: 10.2165/00003088-200847020-00004.
